While the cardiovascular safety of DPP-4 inhibitors has been established in the general type 2 diabetes mellitus (T2DM) population, the cardiovascular safety in DM1 patients, who already have a high risk of arrhythmias and heart failure, remains uncertain. The gene discussed is DPP4; the disease is cardiac arrhythmia.